X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SUN PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SUN PHARMA TORRENT PHARMA/
SUN PHARMA
 
P/E (TTM) x 44.8 37.6 119.0% View Chart
P/BV x 6.3 4.0 157.6% View Chart
Dividend Yield % 0.8 0.3 257.4%  

Financials

 TORRENT PHARMA   SUN PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
SUN PHARMA
Mar-18
TORRENT PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,550701 221.3%   
Low Rs1,144433 264.0%   
Sales per share (Unadj.) Rs354.7110.4 321.3%  
Earnings per share (Unadj.) Rs40.111.0 365.1%  
Cash flow per share (Unadj.) Rs64.217.2 372.8%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %1.00.4 294.6%  
Book value per share (Unadj.) Rs273.1158.8 172.0%  
Shares outstanding (eoy) m169.222,399.26 7.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.85.1 74.0%   
Avg P/E ratio x33.651.6 65.1%  
P/CF ratio (eoy) x21.032.9 63.7%  
Price / Book Value ratio x4.93.6 138.1%  
Dividend payout %34.918.2 191.7%   
Avg Mkt Cap Rs m227,8971,360,021 16.8%   
No. of employees `00014.717.8 82.6%   
Total wages/salary Rs m11,35353,671 21.2%   
Avg. sales/employee Rs Th4,083.014,890.9 27.4%   
Avg. wages/employee Rs Th772.33,017.1 25.6%   
Avg. net profit/employee Rs Th461.31,480.6 31.2%   
INCOME DATA
Net Sales Rs m60,021264,895 22.7%  
Other income Rs m2,9888,388 35.6%   
Total revenues Rs m63,009273,282 23.1%   
Gross profit Rs m13,49356,081 24.1%  
Depreciation Rs m4,08614,998 27.2%   
Interest Rs m3,0855,176 59.6%   
Profit before tax Rs m9,31044,295 21.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m2,5298,452 29.9%   
Profit after tax Rs m6,78126,338 25.7%  
Gross profit margin %22.521.2 106.2%  
Effective tax rate %27.219.1 142.3%   
Net profit margin %11.39.9 113.6%  
BALANCE SHEET DATA
Current assets Rs m52,623316,359 16.6%   
Current liabilities Rs m52,022198,643 26.2%   
Net working cap to sales %1.044.4 2.3%  
Current ratio x1.01.6 63.5%  
Inventory Days Days12095 126.1%  
Debtors Days Days76108 70.8%  
Net fixed assets Rs m85,016213,178 39.9%   
Share capital Rs m8462,399 35.3%   
"Free" reserves Rs m45,376378,606 12.0%   
Net worth Rs m46,222381,006 12.1%   
Long term debt Rs m41,11517,721 232.0%   
Total assets Rs m142,432643,028 22.2%  
Interest coverage x4.09.6 42.0%   
Debt to equity ratio x0.90 1,912.5%  
Sales to assets ratio x0.40.4 102.3%   
Return on assets %6.94.9 141.3%  
Return on equity %14.76.9 212.2%  
Return on capital %14.210.0 141.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58040,816 35.7%   
Fx outflow Rs m3,60030,143 11.9%   
Net fx Rs m10,98010,673 102.9%   
CASH FLOW
From Operations Rs m8,94239,072 22.9%  
From Investments Rs m-47,070-33,708 139.6%  
From Financial Activity Rs m34,174-15,393 -222.0%  
Net Cashflow Rs m-3,655-7,359 49.7%  

Share Holding

Indian Promoters % 71.5 63.7 112.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 5.1 136.8%  
FIIs % 12.6 23.0 54.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 8.3 106.0%  
Shareholders   26,511 133,026 19.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  FULFORD INDIA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS